Send me real-time posts from this site at my email

Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today

What happened

Amylyx Pharmaceuticals (NASDAQ: AMLX), a clinical-stage biopharma, is off to a good start this week. Shares of the small-cap biotech are up by a healthy 12%, on above-average volume, as of 11:54 a.m. ET Tuesday morning.

What's sparking this double-digit rally? Amylyx's shares are responding positively to the news that the Food and Drug Administration (FDA) has decided to reconvene a panel of experts to discuss the pros and cons of the experimental amyotrophic lateral sclerosis (ALS) drug AMX0035.

So what

Earlier this year, this expert panel voted six to four against approving AMX0035 as a treatment for ALS. The company said that additional analyses on the drug's clinical trial data had led to a major amendment regarding this filing, prompting the FDA to take a second look. The agency is now slated to make a final decision on AMX0035 by Sept. 29, 2022. The drug's target action date was previously scheduled for June 29, 2022.

Now what

Is Amylyx stock a screaming buy after this regulatory update? It's hard to say. On the one hand, ALS is an indication that could easily produce blockbuster sales (greater than $1 billion per year). That's a tidy sum for a company with a market cap of approximately $1.3 billion at the moment.

The problem is that the degree of risk involved with this key regulatory decision is hard to decipher. Speaking to this point, Amylyx didn't provide much in the way of details about the analyses that had led to this change of heart at the FDA. Without more information, this biotech is arguably suited only for investors with a high tolerance for risk.

10 stocks we like better than Amylyx Pharmaceuticals, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Amylyx Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 2, 2022

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue